Background Category III “emerging technology” codes were introduced in 2002 as a way to collect data on new procedures, but some payors also recognize some of these codes for reimbursement purposes.

Add-on CPT code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ DVS, together referred to as LumiSystem™, with commercial availability in Q4 2024 ...

The new CPT code, which becomes effective January 1, 2023, will potentially be used by providers performing the VenoValve® procedure on patients across the United States.